AF710B (aka ANAVEX 3-71), is a brain-penetrable mono-therapy that bridges treatment of both cognitive impairments with disease modifications.
AF710B is effective against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and has also demonstrated beneficial effects on neuroinflammation and mitochondrial dysfunctions1.
Similarly, AF710B long-term treatment reverted the cognitive deficits associated with advanced Alzheimer-like amyloid neuropathology in McGill-R-Thy1-APP transgenic rats2. These effects were accompanied by reductions in amyloid pathology and markers of neuroinflammation and increases in amyloid cerebrospinal fluid clearance and levels of a synaptic marker.
With long-lasting disease-modifying properties at low dose, AF710B is a promising novel therapeutic agent for treating Alzheimer's and other related diseases.
AF710B (ANAVEX 3-71) and its patents were licensed for further development. U.S. FDA Granted Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia.
AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease. Fisher A, Bezprozvanny I, Wu L, Ryskamp DA, Bar-Ner N, Natan N, Brandeis R, Elkon H, Nahum V, Gershonov E, LaFerla FM, Medeiros R. Neurodegener Dis. 2016;16(1-2):95-110;
AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease. Hall H, Iulita MF, Gubert P, Flores Aguilar L, Ducatenzeiler A, Fisher A, Cuello AC Alzheimer's & Dementia. 2017 Dec 29. pii: S1552-5260(17)33851-7. doi: 10.1016/j.jalz.2017.11.009. [Epub ahead of print]
A. Fisher, N. Bar-Ner, Victoria Nahum Bicyclic heterocyclic spiro compounds, US 8,673,931 B2 Mar. 18, 2014.The composition and method Patent covers AF710B for treating Alzheimer’s disease, type 2 diabetes and insulin resistance. The Patent has a term that expires no earlier than April 29, 2030.
A. Fisher, N. Bar-Ner, Victoria Nahum Bicyclic heterocyclic spiro compounds, US 9,034,891 B2 May. 19, 2015.
We welcome you to contact us for any question or offer for collaborations.
There are some errors in your form.
the mail is recived, thank you